PARI Pharma, a German manufacturer of aerosol delivery products, won FDA approval of its LAMIRA nebulizer along with Insmed‘s ARIKAYCE (amikacin liposome inhalation suspension) drug for treating lung infections caused by the mycobacterium avium complex (MAC), a group of bacteria that are difficult to treat in many patients.
The approval of t (Read more...)